| KEDRION |
KEDRION |
92%
|
Sales to Kedrion accounted for approximately 30%, 31% and 23% of our total revenues in the years ended December 31, 2025, 2024 and 2023, respectively. |
| BAX |
Baxter International Inc. |
85%
|
Reciprocal relationship from BAX graph: Reciprocal relationship from KMDA graph: 2010, the Company entered into a 30 -year collaboration agreement with Baxter Healthcare Corporation (“Baxter”) with r… |
| BAXALTA-US-INC |
BAXALTA-US-INC |
85%
|
er assigned all its rights under the collaboration agreement to Baxalta US Inc. (“Baxalta”) which was acquired during 2016 by Shire plc. (“Shire”), which is now part of Takeda (“Takeda” and in these … |
| BAXTER-HEALTHCARE-CORPORATION |
BAXTER-HEALTHCARE-CORPORATION |
85%
|
2010, the Company entered into a 30 -year collaboration agreement with Baxter Healthcare Corporation (“Baxter”) with respect for granting of the distribution rights for GLASSIA. During 2015, Baxter a… |
| BIOTEST-AG |
BIOTEST-AG |
85%
|
/or at a reasonable cost, would have a material adverse effect on our business, financial condition and results of operations. Sales of products supplied by Biotest AG, Kedrion, Chiesi Farmaceutici S… |
| CSL-BEHRING-LTD |
CSL-BEHRING-LTD |
85%
|
as our future results of operations and profitability. CYTOGAM is manufactured at our facility in Beit Kama, Israel since 2023. To manufacture CYTOGAM, we engaged Prothya Biosolutions Belgium (“Proth… |
| KEDRION-KEDPLASMA-LLC |
KEDRION-KEDPLASMA-LLC |
85%
|
31, 2033. We currently also purchase from a subsidiary of Kedrion, KedPlasma LLC (“Kedplasma”), a large portion of the hyper-immune plasma, which is used for the production of KEDRAB/KAMRAB. See “— W… |
| ALVO |
Alvotech |
72%
|
Reciprocal relationship from ALVO graph: Reciprocal relationship from KMDA graph: License Application (BLA) of the product, in consideration for a $ million payment from Takeda, which was paid by Tak… |
| ALVO |
Alvotech |
72%
|
License Application (BLA) of the product, in consideration for a $ million payment from Takeda, which was paid by Takeda and accounted for as income during the first quarter of 2022. Commencing 2022,… |
| CHKP |
Check Point Software Technologies Ltd. |
72%
|
they will be utilized. Deductible carryforward losses and temporary differences for which deferred tax assets have not been recognized are reviewed at the end of each reporting period, and a respecti… |
| CHKP |
Check Point Software Technologies Ltd. |
72%
|
Reciprocal relationship from CHKP graph: Reciprocal relationship from KMDA graph: Reciprocal relationship from CHKP graph: Reciprocal relationship from KMDA graph: they will be utilized. Deductible c… |
| GILT |
Gilat Satellite Networks Ltd. |
72%
|
they will be utilized. Deductible carryforward losses and temporary differences for which deferred tax assets have not been recognized are reviewed at the end of each reporting period, and a respecti… |
| GILT |
Gilat Satellite Networks Ltd. |
72%
|
Reciprocal relationship from GILT graph: Reciprocal relationship from KMDA graph: they will be utilized. Deductible carryforward losses and temporary differences for which deferred tax assets have no… |
| ICL |
ICL Group Ltd |
72%
|
Reciprocal relationship from ICL graph: Reciprocal relationship from KMDA graph: Reciprocal relationship from ICL graph: Reciprocal relationship from KMDA graph: they will be utilized. Deductible car… |
| ICL |
ICL Group Ltd |
72%
|
they will be utilized. Deductible carryforward losses and temporary differences for which deferred tax assets have not been recognized are reviewed at the end of each reporting period, and a respecti… |
| NVSEF |
Novartis AG |
72%
|
Reciprocal relationship from NVSEF graph: Reciprocal relationship from KMDA graph: Reciprocal relationship from NVSEF graph: Reciprocal relationship from KMDA graph: Reciprocal relationship from NVSE… |
| NVSEF |
Novartis AG |
72%
|
sell products in the Distribution segment in Israel, we must register the products, at our own expense, with the IMOH. We cannot predict how long the registration process of the IMOH may take or whet… |
| PPBT |
Purple Biotech Ltd |
72%
|
Reciprocal relationship from PPBT graph: Reciprocal relationship from KMDA graph: Reciprocal relationship from PPBT graph: Reciprocal relationship from KMDA graph: they will be utilized. Deductible c… |
| PPBT |
Purple Biotech Ltd |
72%
|
they will be utilized. Deductible carryforward losses and temporary differences for which deferred tax assets have not been recognized are reviewed at the end of each reporting period, and a respecti… |
| SNYNF |
Sanofi |
72%
|
sell products in the Distribution segment in Israel, we must register the products, at our own expense, with the IMOH. We cannot predict how long the registration process of the IMOH may take or whet… |
| SNYNF |
Sanofi |
72%
|
Reciprocal relationship from SNYNF graph: Reciprocal relationship from KMDA graph: Reciprocal relationship from SNYNF graph: Reciprocal relationship from KMDA graph: sell products in the Distribution… |
| VALN |
Valneva SE |
72%
|
Reciprocal relationship from VALN graph: Reciprocal relationship from KMDA graph: tici S.p.A, Bio Products Laboratories (“BPL”) and Valneva SE, which are sold in our Distribution segment, together re… |
| VALN |
Valneva SE |
72%
|
tici S.p.A, Bio Products Laboratories (“BPL”) and Valneva SE, which are sold in our Distribution segment, together represented approximately 8%, 18% and 20% of our total revenues for the years ended … |
| ADMA |
ADMA Biologics, Inc. |
62%
|
Reciprocal relationship from ADMA graph: Reciprocal relationship from KMDA graph: ts compete with products distributed by well-established biopharmaceutical companies, including several large competi… |
| ADMA-BIOLOGICS-INC |
ADMA-BIOLOGICS-INC |
62%
|
ts compete with products distributed by well-established biopharmaceutical companies, including several large competitors in the plasma industry. These large competitors include CSL Behring, Takeda, … |
| CAPITAL-RESOURCES |
CAPITAL-RESOURCES |
62%
|
tion products or product candidates may infringe or be accused of infringing one or more claims of an issued patent or may fall within the scope of one or more claims in a published patent applicatio… |
| KAMADA-PLASMA-LLC |
KAMADA-PLASMA-LLC |
62%
|
31, 2025, 2024 and 2023, the Company recognized net revenues of $ 17,113 thousands, $ 22,521 thousands and $ 17,180 thousands, respectively from sales of CYTOGAM. ● Sales milestones: two $ 1,500 thou… |
| KEDRAB-BIOTEST-AG |
KEDRAB-BIOTEST-AG |
62%
|
ts compete with products distributed by well-established biopharmaceutical companies, including several large competitors in the plasma industry. These large competitors include CSL Behring, Takeda, … |
| KEDRION-BIOPHARMA-INC |
KEDRION-BIOPHARMA-INC |
62%
|
tes in the United States and will also collect normal source plasma for sale to third parties ; our expectation that our plasma collection site in San Antonio, Texas will receive FDA approval during … |
| SARTORIUS-STEDIM-BIOTECH-GROUP |
SARTORIUS-STEDIM-BIOTECH-GROUP |
62%
|
er. In August 2025, we received FDA supplemental approval for NSP collection operations at the Houston center. In May 2024, we entered into a lease agreement for a facility in San Antonio, Texas, and… |
